Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers-Reference-Cited by-同舟云学术

Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers

Published:2024-04-30 Issue:9 Volume:16 Page:1370
ISSN:2072-6643
Container-title:Nutrients
language:en
Short-container-title:Nutrients

Author:

Kiljańczyk Adam¹,Matuszczak Milena¹^ORCID,Marciniak Wojciech²^ORCID,Derkacz Róża²^ORCID,Stempa Klaudia¹,Baszuk Piotr¹²^ORCID,Bryśkiewicz Marta¹²,Lubiński Krzysztof¹,Cybulski Cezary¹²,Dębniak Tadeusz¹²^ORCID,Gronwald Jacek¹²^ORCID,Huzarski Tomasz¹²³,Lener Marcin R.¹,Jakubowska Anna¹^ORCID,Szwiec Marek⁴^ORCID,Stawicka-Niełacna Małgorzata³^ORCID,Godlewski Dariusz⁵,Prusaczyk Artur⁶,Jasiewicz Andrzej⁷^ORCID,Kluz Tomasz⁸^ORCID,Tomiczek-Szwiec Joanna⁹^ORCID,Kilar-Kobierzycka Ewa¹⁰,Siołek Monika¹¹,Wiśniowski Rafał¹²,Posmyk Renata¹³,Jarkiewicz-Tretyn Joanna¹⁴,Sun Ping¹⁵,Scott Rodney J.¹⁶^ORCID,Narod Steven A.¹⁵^ORCID,Lubiński Jan¹²^ORCID

Affiliation:

1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland

2. Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland

3. Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland

4. Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland

5. OPEN, Kazimierza Wielkiego 24 Str., 61-863 Poznań, Poland

6. Medical and Diagnostic Center, Niklinowa 9, 08-110 Siedlce, Poland

7. Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego Str., 36-200 Brzozów, Poland

8. Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland

9. Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland

10. Department of Oncology, District Specialist Hospital, Leśna 27-29 Str., 58-100 Świdnica, Poland

11. Holycross Cancer Center, Artwińskiego 3 Str., 25-734 Kielce, Poland

12. Regional Oncology Hospital, Wyzwolenia 18 Str., 43-300 Bielsko Biała, Poland

13. Department of Clinical Genetics, Podlaskie Medical Center, 15-399 Bialystok, Poland

14. Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toruń, Poland

15. Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada

16. Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia

Abstract

BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23–9.00; p = 0.02; multivariable: HR = 2.10; 95% CI: 0.73–6.01; p = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.

Funder

Minister of Science and Higher Education

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6643/16/9/1370/pdf

Reference19 articles.

1. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers;Kuchenbaecker;JAMA,2017

2. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants;Li;J. Clin. Oncol.,2022

3. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis;Friebel;J. Natl. Cancer Inst.,2014

4. Marciniak, W., Matoušek, T., Domchek, S., Paradiso, A., Patruno, M., Irmejs, A., Roderte, I., Derkacz, R., Baszuk, P., and Kuświk, M. (2021). Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. Cancers, 13.

5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Inorganic and Organic Lead Compounds;Levy;IARC Monogr. Eval. Carcinog. Risks Hum.,2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between weight-adjusted-waist index and gynecologic cancers: a population-based study;Frontiers in Nutrition;2024-09-13

2. The preventive and carcinogenic effect of metals on cancer: a systematic review;BMC Public Health;2024-08-01

3. Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers;Antioxidants;2024-07-14

4. Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers;Nutrients;2024-06-06